Vivani Medical announced the successful dosing of all participants in its SLIM-1 Phase 1 clinical trial for NPM-139, a miniature subdermal semaglutide implant designed for chronic weight management. The trial enrolled 20 GLP-1 naïve participants in Australia, with initial dosing completed ahead of schedule on July 29 and the remaining participants dosed one week later without issues. Top-line data regarding safety, tolerability, and pharmacokinetics is expected in November 2026. This milestone follows a July 2026 agreement with Novo Nordisk to evaluate NPM-139 and Vivani's proprietary NanoPortal technology. The company anticipates initiating a Phase 2 dose-ranging trial in 2027 based on these results. Vivani Medical operates in the biopharmaceutical industry, developing miniature implants for extended drug delivery.
